ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,303.27
0.12%
US Tech 100
18,066.00
-0.07%
다우존스 지수
40,003.59
0.34%
Bitcoin
66,929.94
-0.22%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Lipella Pharmaceuticals Inc (LIPO)

  7. Lipella Pharmaceuticals Inc (LIPO) 뉴스

LIPO

Lipella Pharmaceuticals (LIPO)

Lipella Pharmaceuticals Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:LIPO
일자시간출처헤드라인심볼기업
2024/05/1605:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIPOLipella Pharmaceuticals Inc
2024/05/1005:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LIPOLipella Pharmaceuticals Inc
2024/05/0705:05Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:LIPOLipella Pharmaceuticals Inc
2024/04/1721:00GlobeNewswire Inc.Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology ExpertiseNASDAQ:LIPOLipella Pharmaceuticals Inc
2024/04/0521:00GlobeNewswire Inc.Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024NASDAQ:LIPOLipella Pharmaceuticals Inc
2024/04/0321:00GlobeNewswire Inc.Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic CystitisNASDAQ:LIPOLipella Pharmaceuticals Inc
2024/03/0805:23GlobeNewswire Inc.PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare DiseaseNASDAQ:LIPOLipella Pharmaceuticals Inc
2024/03/0707:05Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:LIPOLipella Pharmaceuticals Inc
2024/03/0707:03Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:LIPOLipella Pharmaceuticals Inc
2024/03/0522:00GlobeNewswire Inc.Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical PipelineNASDAQ:LIPOLipella Pharmaceuticals Inc
2024/02/2807:04Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LIPOLipella Pharmaceuticals Inc
2024/02/2806:51Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:LIPOLipella Pharmaceuticals Inc
2024/02/2022:00GlobeNewswire Inc.Lipella Pharmaceuticals to Present at PropThink Digital Investor ConferenceNASDAQ:LIPOLipella Pharmaceuticals Inc
2024/02/0914:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LIPOLipella Pharmaceuticals Inc
2024/02/0807:29Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LIPOLipella Pharmaceuticals Inc
2024/02/0206:09Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LIPOLipella Pharmaceuticals Inc
2024/01/2606:06Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LIPOLipella Pharmaceuticals Inc
2024/01/0406:59Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:LIPOLipella Pharmaceuticals Inc
2023/12/2022:00GlobeNewswire Inc.Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones AccomplishedNASDAQ:LIPOLipella Pharmaceuticals Inc
2023/11/2907:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIPOLipella Pharmaceuticals Inc
2023/11/2306:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIPOLipella Pharmaceuticals Inc
2023/11/1420:22Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LIPOLipella Pharmaceuticals Inc
2023/11/1420:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LIPOLipella Pharmaceuticals Inc
2023/11/1022:00PR Newswire (US)FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host DiseaseNASDAQ:LIPOLipella Pharmaceuticals Inc
2023/11/1006:07Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LIPOLipella Pharmaceuticals Inc
2023/11/0914:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LIPOLipella Pharmaceuticals Inc
2023/11/0807:22Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:LIPOLipella Pharmaceuticals Inc
2023/11/0205:06Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:LIPOLipella Pharmaceuticals Inc
2023/10/2605:05PR Newswire (US)Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq RulesNASDAQ:LIPOLipella Pharmaceuticals Inc
2023/10/2421:00PR Newswire (US)Lipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq RulesNASDAQ:LIPOLipella Pharmaceuticals Inc
 검색 관련기사 보기:NASDAQ:LIPO

최근 히스토리

TSX
PLC.DB
Park Lawn
COIN
HIZUSD
ASE
G101221A2
Greece
NYSE
CIM-C
Chimera Investment
Delayed Upgrade Clock
ADVFN Logo

대한민국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유